Keros Therapeutics (KROS) Equity Average (2019 - 2025)

Keros Therapeutics has reported Equity Average for 7 years, with the latest figure at $503.4 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average fell 8.84% year-over-year to $503.4 million; the trailing twelve-month figure through Dec 2025 stood at $503.4 million (down 8.84% YoY), and the FY2025 full-year result was $437.3 million, down 3.22% from the prior year.
• Equity Average for Q4 2025 stood at $503.4 million, down from $705.2 million in the prior quarter.
• The five-year high for Equity Average was $717.8 million in Q2 2025, with the low at $217.4 million in Q2 2022.
• Historically, Equity Average has averaged $380.4 million across 5 years, with a median of $315.1 million in 2023.
• Annual changes were most pronounced in 2021 — Equity Average jumped 1251.11% — and 2022, when it decreased 10.19%.
• Keros Therapeutics' Equity Average stood at $230.8 million in 2021, then gained by 12.3% to $259.2 million in 2022, then gained by 21.14% to $314.0 million in 2023, then soared by 75.84% to $552.2 million in 2024, then fell by 8.84% to $503.4 million in 2025.
• The last three Equity Average figures came in at $503.4 million (Q4 2025), $705.2 million (Q3 2025), and $717.8 million (Q2 2025), per Business Quant data.